IDXX
IDEXX Laboratories Inc
NASDAQ: IDXX · HEALTHCARE · DIAGNOSTICS & RESEARCH
$532.00
-0.46% today
Updated 2026-06-05
Market cap
$44.24B
P/E ratio
41.33
P/S ratio
9.95x
EPS (TTM)
$13.57
Dividend yield
—
52W range
$507 – $770
Volume
0.6M
WallStSmart proprietary scores
63
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B7.0
Quality
B+9.5
Profitability
A+2.7
Valuation
F6/9
Piotroski F-Score
Moderate
5.9
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$712.00
+33.83%
12-Month target
$392.50
-26.22%
Intrinsic (DCF)
$423.77
Margin of safety
-53.09%
4 Strong Buy5 Buy5 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 5.92 — safe zone
+ Profit margin 24.60% — above average
+ ROE 70.38% — strong efficiency
+ Free cash flow $234.26M — positive
+ Revenue growth 14.30% QoQ
Risks
- 53.09% above intrinsic value
- P/E 41.33x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $3.37B | $3.66B | $3.90B | $4.30B | $4.45B | $4.7B |
| Net income | $679.09M | $845.04M | $887.87M | $1.06B | $278.45M | — |
| EPS | — | — | — | — | $13.57 | $14.82 |
| Free cash flow | $394.15M | $772.88M | $798.08M | $1.05B | $234.26M | — |
| Profit margin | 20.17% | 23.08% | 22.78% | 24.62% | 24.60% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | FENNELL, GEORGE | Sale | 639 | — |
| 2026-06-01 | FENNELL, GEORGE | Buy | 639 | — |
| 2026-06-01 | FENNELL, GEORGE | Sale | 284 | $566.79 |
Peer comparison
Smart narrative
IDEXX Laboratories Inc trades at $532.00. representing a P/E of 41.33x trailing earnings. Our Smart Value Score of 63/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 5.92, it sits in the safe zone. TTM revenue stands at $4.45B. with profit margins at 24.60%. Our DCF model estimates intrinsic value at $423.77.
Frequently asked questions
What is IDEXX Laboratories Inc's stock price?
IDEXX Laboratories Inc (IDXX) trades at $532.00, on a P/E of 41.3x and a P/S of 10.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is IDEXX Laboratories Inc overvalued?
IDEXX Laboratories Inc carries a Smart Value Score of 63/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $423.77 against the $532.00 price, so on cash flow terms the market is paying a premium for IDEXX Laboratories Inc's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of IDEXX Laboratories Inc (IDXX)?
The 12-month analyst consensus target is $712.00, about 33.8% above the current $532.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of IDXX by 2030?
Our research-backed model puts the 2030 base case at $968.23, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of IDEXX Laboratories Inc (IDXX)?
Our DCF model estimates intrinsic value at $423.77, a -53.1% margin of safety versus today's $532.00. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is IDEXX Laboratories Inc's revenue?
IDEXX Laboratories Inc's trailing twelve-month revenue is $4.45B, and our model projects it reaching about $6.50B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
IDEXX Laboratories Inc's Altman Z-Score is 5.92, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.95x
ROE70.38%
Beta1.54
50D MA$563.10
200D MA$634.13
Shares out0.08B
Float0.08B
Short ratio—
Avg volume0.6M
Performance
1 week+0.00%
1 month+6.31%
3 months-2.03%
YTD-16.91%
1 year—
3 years—
5 years—